Objective-To examine the effect of doubling serum magnesium concentration on the incidence of arrhythmias in patients with suspected acute myocardial infarction. Design-Randomised double blind clinical trial. Several small clinical trials of intravenous magnesium sulphate or chloride in acute myocardial infarction have given mixed results. Attained [Mg2'+] has been substantially lower than in the experimental studies described earlier, in the range 1P0-IS5 mmol/l (normal range approximately 0 70-0 95 mmol/l). Four double blind, randomised trials in a total of nearly 900 patients with suspected or definite acute myocardial infarction showed no significant reduction in any class of ventricular arrhythmia.7-'0 One study (48 patients with confirmed acute myocardial infarction) showed a highly significant reduction in incidence of ventricular tachycardia in the magnesium group but a higher incidence of other ventricular arrhythmias."1 Two randomised trials, each of fewer than 50 patients, reported significant reductions in the incidence of ventricular arrhythmias."2"3 A further randomised trial in which 130 patients with confirmed acute myocardial infarction received either intravenous magnesium chloride or placebo showed a highly significant reduction in the incidence of supraventricular tachycardias in the magnesium group but no effect on ventricular arrhythmias."4 Pooled analysis of the arrhythmia data in these trials is unhelpful because of the differing definitions of rhythm end points.
Investigation of the effects of intravenous magnesium sulphate on cardiac rhythm in acute myocardial infarction C Roffe, S Fletcher, K L Woods Abstract Objective-To examine the effect of doubling serum magnesium concentration on the incidence of arrhythmias in patients with suspected acute myocardial infarction. Design-Randomised double blind clinical trial. Setting-Coronary care unit of a teaching hospital. Patients-Clinical data were collected on 2316 randomised patients with suspected acute myocardial infarction. Holter monitoring was performed in a subgroup of 70 patients and analysed in 48 patients in whom acute myocardial infarction was confirmed. Interventions-By random allocation, patients received either an intravenous loading dose of 8 mmol magnesium sulphate over five minutes plus 65 mmol over the next 24 hours, or equal volumes of saline. Main outcome measures-(a) Clinically documented arrhythmias; (b) use of antiarrhythmic treatments, cardioversion, and insertion of a pacemaker; (c) incidence of all abnormal rhythms during Holter monitoring. Results-In the main trial the incidence of rhythm disturbance while in the coronary care unit (expressed as the odds ratio (OR) for magnesium: placebo and its 95% confidence interval) was not significantly different between treatment groups for ventricular fibrillation (OR 0 74; 0-46 to 1.20) , ventricular tachycardia (OR 0-87; 0-63 to [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , supraventricular tachycardia (OR 0-69; 0-38 to 1.26) , atrial fibrillation (OR 0-92; 0-69 to 1.23), or heart block of any degree (OR 1-17; 0*83 to 1.65 (48 patients with confirmed acute myocardial infarction) showed a highly significant reduction in incidence of ventricular tachycardia in the magnesium group but a higher incidence of other ventricular arrhythmias."1 Two randomised trials, each of fewer than 50 patients, reported significant reductions in the incidence of ventricular arrhythmias."2"3 A further randomised trial in which 130 patients with confirmed acute myocardial infarction received either intravenous magnesium chloride or placebo showed a highly significant reduction in the incidence of supraventricular tachycardias in the magnesium group but no effect on ventricular arrhythmias."4 Pooled analysis of the arrhythmia data in these trials is unhelpful because of the differing definitions of rhythm end points.
We have therefore analysed all available data on the frequency of arrhythmias in a large double blind trial (the second Leicester intravenous magnesium intervention trial LIMIT-2) study) in which 2316 patients with suspected acute myocardial infarction were randomly allocated to receive intravenous magnesium sulphate or saline for 24 hours after admission. In this study 28 day mortality was the primary endpoint and frequency of arrhythmia within the coronary care unit a secondary endpoint defined in the protocol. Three methods (each blind to treatment allocation) were used to identify a possible antiarrhythmic effect of magnesium: an analysis of all arrhythmias recorded clinically in trial patients during routine monitoring while in the coronary care unit; analysis of the use of antiarrhythmic treatments specified by the protocol; and a Holter monitoring study in a representative subgroup of trial patients to quantify all abnormal rhythms. A summary of the data from the first two analyses were presented in brief in the first trial report."5
Patients and methods The protocol of LIMIT-2 and data on 28 day mortality and early morbidity have been described elsewhere.'5 Briefly, consenting patients entering the coronary care unit of Leicester Royal Infirmary between September 1987 and February 1992 were eligible for randomisation if they were suspected of having acute myocardial infarction of less than 24 hours in duration. Exclusion criteria were complete heart block or serum creatinine > 300 ,umol/l. The trial treatment was 8 mmol magnesium sulphate infused intravenously over five minutes, then 65 mmol over 24 hours. The placebo treatment was an equal volume of saline. The magnesium regimen raised serum [Mg2 +] to a mean of 1-5 mmol/l for the duration of treatment; the concentration then declined to the normal range during a further 24 hours. Trial treatments were supplied in identical coded packs and the allocation code was not broken until the end of the trial. Analysis was by intention to treat. 24 hours after randomisation in a subgroup of 70 patients entering the trial. The diagnosis of acute myocardial infarction was subsequently confirmed in 51 of these, in three of whom the recordings were technically inadequate. The analysis was carried out on the remaining 48 patients with confirmed acute myocardial infarction, among whom the recording was incomplete for two patients in the placebo group because of a premature end when emergency cardioversion was given for ventricular fibrillation. These patients were included in the analysis of incidence of arrhythmia but could not be included in the analysis of frequency of events over 24 hours. Extrapolation from the available recordings from these two patients was considered to be invalid as there was a strong general trend to lower hourly rates of events over the recording period. Tapes were analysed by computer, with visual verification of all abnormal rhythms. All data were collected without knowledge of the patients' treatment group. Ventricular tachycardia was defined as the occurrence of > six ventricular extra systoles at a rate >100 beats/min and >120% of the sinus rate. Runs not meeting these criteria were classified as salvos.
Hypotheses were tested byZ2 and MannWhitney statistics.
Results
The incidence of clinically documented tachycardias in the trial groups was not significantly different for ventricular fibrillation, ventricular tachycardia, supraventricular tachycardia, or atrial fibrillation (fig 1) although each was slightly less common in the magnesium group. Heart block, whether analysed by grade of block or pooling all grades, was of similar incidence in both groups (table 1 ). The only difference in cardiac rhythm that reached significance between the groups was the documentation of sinus bradycardia, which was recorded in 108% of the magnesium group and 8-0% of the placebo group (p = 002). Table 2 shows the effects as odds ratios (ORs) and their 95% confidence intervals (95% CIs). These findings are supported by the data on treatments used and procedures performed. There was a slightly lower incidence of the use of lignocaine, amiodarone, and digoxin in the magnesium group but none of the comparisons reached significance (fig 2) . Insertion of a temporary pacemaker and direct current cardioversion were similar in the two groups. Consistent with the significant excess of sinus bradycardia in the magnesium group, there was a correspondingly higher rate of use of atropine (p < 0-001). A detailed analysis of mortality and morbidity in the trial shows no evidence that the occurrence of sinus bradycardia was deleterious"5; left ventricular failure in the coronary care unit and 28 day mortality were both significantly lower in the magnesium group. Among the analysable patients included in the Holter monitoring study who had a confirmed acute myocardial infarction, 22 received magnesium sulphate and 26 placebo. Table 3 shows their clinical characteristics. The incidence of the various classes of disturbance of ventricular rhythm detected during Holter monitoring (fig 3) was not significantly different in the two groups. Because the numbers of events in each class were not normally (table 4) by their median values and comparisons were tested by a non-parametric method (MannWhitney test). No significant differences were found in the amount of any class of ventricular arrhythmia that occurred during the 24 hours of recording.
Discussion
The LIMIT-2 study is by far the largest randomised trial in which the possible prophylactic value of an intravenous magnesium salt against ischaemic arrhythmias has been examined. Although the identification of arrhythmias from routine continuous monitoring is known to be incomplete, the likelihood of detection is in proportion to the clinical significance of the arrhythmia. Moreover, the double blind design of the protocol and the corroboration provided by the analysis of antiarrhythmic treatments given support the validity of the findings from the main study. The Holter monitoring study in a representative group of patients with confirmed myocardial infarction, designed to achieve complete and accurate ascertainment of all disturbances of rhythm, also showed no significant antiarrhythmic effect of magnesium.
The apparent discrepancy between the findings of our study and the experimental models of myocardial ischaemia2-6 may reflect the difference in the extemal There is a small but consistent prolongation of the atrium-His interval due to slowing of conduction through the upper AV node. This action may account for the reported efficacy of magnesium salts in the treatment of AV re-entrant supraventricular tachycardia; it seems to arise from competitive blockade of the slow Ca2+ channel and resembles the action of the organic calcium antagonist verapamil.
Because of the reported effect of Mg2 + on conduction through the AV node, evidence was sought in our study for any association between magnesium treatment and the development or exacerbation of heart block; none was found. The increased incidence of sinus bradycardia was not predicted by electrophysiological studies of intravenous Mg2 + in humans, which have indicated a lack of effect on the length of the sinus node cycle. In these studies a direct inhibition of the sinus node by Mg2 + through an effect on the slow Ca2 + channel or the acetylcholine activated K + channel27 might have been offset by the reflex response to peripheral vasodilatation induced by Mg2 +, but if so it is unclear why our group of patients should have responded differently. A more likely explanation is that the relatively small electrophysiological studies lacked the statistical power to detect a modest Mg2 + effect.
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